C
ARQT icon

Covestor’s Arcutis Biotherapeutics ARQT Stock Holding History

Covestor’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56K Buy
2,136
+2,128
+26,600% +$49.6K 0.03% 728
2026
Q1 		$0 Sell
8
-1
-11% -$26 ﹤0.01% 2239
2025
Q4 		$0 Hold
9
– – ﹤0.01% 2245
2025
Q3 		$0 Hold
9
– – ﹤0.01% 2264
2025
Q2 		$0 Sell
9
-1
-10% -$14 ﹤0.01% 2187
2025
Q1 		$0 Hold
10
– – ﹤0.01% 2190
2024
Q4 		$0 Buy
10
+1
+11% +$11 ﹤0.01% 2207
2024
Q3 		$0 Sell
9
-1
-10% -$10 ﹤0.01% 2187
2024
Q2 		$0 Hold
10
– – ﹤0.01% 2219
2024
Q1 		$0 Sell
10
-8
-44% -$60 ﹤0.01% 2213
2023
Q4 		$0 Buy
18
+11
+157% +$30 ﹤0.01% 2119
2023
Q3 		$0 Sell
7
-1
-13% -$9 ﹤0.01% 2088
2023
Q2 		$0 Hold
8
– – ﹤0.01% 2105
2023
Q1 		$0 Hold
8
– – ﹤0.01% 1990
2022
Q4 		$0 Sell
8
-1
-11% -$17 ﹤0.01% 2035
2022
Q3 		$0 Sell
9
-1
-10% -$23 ﹤0.01% 1954
2022
Q2 		$0 Buy
+10
New +$205 ﹤0.01% 1879
2022
Q1 		– Sell
-16
Closed – – 2080
2021
Q4 		$0 Buy
+16
New +$318 ﹤0.01% 2096

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Covestor's ARQT Position: Q2 2026 in Review

Covestor increased its Arcutis Biotherapeutics (ARQT) stake by 26,600% in Q2 2026, buying an estimated $49.6K and bringing the position to 2,136 shares worth $56K. The position accounts for 0.03% of the portfolio, ranked #728.

Covestor first reported a position in ARQT in Q4 2021 and has held it in 18 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Covestor held 2,136 shares of Arcutis Biotherapeutics worth $56K as of Q2 2026.
  • Covestor bought 2,128 Arcutis Biotherapeutics shares in Q2 2026, an estimated $49.6K.
  • Arcutis Biotherapeutics made up 0.03% of Covestor's portfolio in Q2 2026, its #728 holding.
  • Covestor first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 18 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.